Kenvue Inc. (KVUE)

Market Cap	41.93B
Revenue (ttm)	15.30B
Net Income (ttm)	1.06B
Shares Out	1.92B
EPS (ttm)	0.55
PE Ratio	39.62
Forward PE	18.85
Dividend	$0.82 (3.75%)
Ex-Dividend Date	May 14, 2025

Volume	1,721,714
Open	21.83
Previous Close	21.85
Day's Range	21.76 - 22.02
52-Week Range	17.85 - 25.17
Beta	0.78
Analysts	Buy
Price Target	24.71 (+13.92%)
Earnings Date	Aug 5, 2025

About KVUE

Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• IPO Date: May 4, 2023
• Employees: 22,000
• Stock Exchange: NYSE
• Ticker Symbol: KVUE
• Website: https://www.kenvue.com

Financial Performance

In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.

Analyst Summary

According to 12 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $24.71, which is an increase of 13.92% from the latest price.

Price Target

$24.71

(13.92% upside)

Analyst Consensus: Buy